Syndax Pharmaceuticals Inc (SNDX)
NASDAQ:SNDX
Want to see SNDX full AI Analyst Report?
Top Page
Syndax Pharmaceuticals
(NASDAQ:SNDX)
Select Model
Select Model
Rating:49Neutral
Price Target:
$19.00
▼(-21.58% Downside)
Action:ReiteratedDate:05/02/26
The score is held down primarily by weak financial quality today—large ongoing losses and substantial cash burn—along with a bearish technical setup. Offsetting these, the latest earnings call indicates strong commercial acceleration, expanding market opportunity, and a solid cash position with stated intent to reach profitability without raising capital, supporting a modestly higher overall score despite near-term financial and execution risks.
Positive Factors
Commercial momentum / revenue growth
Quarter-over-quarter acceleration in Revuforj prescriptions and new patient starts demonstrates durable real-world adoption and expanding commercial traction. Sustained prescription growth and growing patient starts support scalable revenue over multiple quarters as label expansion (NPM1) increases addressable population.
Negative Factors
Heavy cash burn / negative cash flow
Sustained negative operating and free cash flow at this magnitude creates structural funding sensitivity. Even with product momentum, the company needs continued revenue scale or expense reductions to avoid dilutive financing; cash burn constrains long-term margin conversion and strategic optionality.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial momentum / revenue growth
Quarter-over-quarter acceleration in Revuforj prescriptions and new patient starts demonstrates durable real-world adoption and expanding commercial traction. Sustained prescription growth and growing patient starts support scalable revenue over multiple quarters as label expansion (NPM1) increases addressable population.
Read all positive factors
Syndax Pharmaceuticals (SNDX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.83B
Dividend YieldN/A
Average Volume (3M)1.45M
Price to Earnings (P/E)―
Beta (1Y)0.94
Revenue Growth397.28%
EPS Growth27.68%
CountryUS
Employees270
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.80
Shares Outstanding88,610,020
10 Day Avg. Volume1,196,539
30 Day Avg. Volume1,452,998
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)28.16
Price to Sales (P/S)10.56
P/FCF Ratio-5.63
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue9.37
Enterprise Value/Gross Profit9.57
Enterprise Value/Ebitda-12.52
Forecast
1Y Price Target
$40.20Price Target Upside65.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-1.77
Revenue Forecast (FY)$348.13M
Syndax Pharmaceuticals Business Overview & Revenue Model
Company Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin wi...
How the Company Makes Money
Syndax primarily makes money by selling its approved prescription oncology drug(s) and recording related net product revenue, which is driven by demand, pricing, and reimbursement dynamics in the markets where it commercializes. Revenue is recogni...
Syndax Pharmaceuticals Key Performance Indicators (KPIs)
Any
Revenue by Type
Reveals how different revenue streams contribute to the overall income, highlighting the company’s diversification and potential reliance on specific products or services.
Reveals how different revenue streams contribute to the overall income, highlighting the company’s diversification and potential reliance on specific products or services.
Data provided by:
The Fly
The FlySyndax Pharmaceuticals Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Aug 10, 2026
Earnings Call Sentiment Positive
The call conveyed strong commercial momentum and meaningful scientific progress: two successful launches, accelerating quarter-over-quarter revenue growth (Revuforj +38% QoQ; Niktimvo +22% QoQ), solid real-world evidence, a healthy year-end cash balance ($394M) and multiple near- and mid-term clinical catalysts (frontline pivotal trials and an IPF readout). Offsetting factors include a high 2026 expense run-rate (~$400M), still-short average treatment duration in year one for Revuforj (4–6 months), incomplete post-transplant maintenance uptake (~40%–45%) and the risk that pending clinical readouts or competitive dynamics could temper expectations. On balance, highlights and growth drivers substantially outweigh near-term risks, but upcoming readouts and execution on duration/maintenance adoption and expense control are critical.Positive Updates
Multiple Approvals and Successful Launches
Syndax launched 2 first- and best-in-class medicines in 2025 and achieved its third FDA approval within ~1 year, demonstrating strong commercial and R&D execution.
Negative Updates
High Operating Expense Run-Rate Versus Current Revenue
2026 guidance for R&D + SG&A of ~ $400M (excl. ~$50M noncash comp) contrasts with 2025 total revenue of $172.4M, implying a high near-term cash burn and substantial investment before (or while) profitability is achieved.
Read all updates
Q4-2025 Updates
Positive
Negative
Multiple Approvals and Successful Launches
Syndax launched 2 first- and best-in-class medicines in 2025 and achieved its third FDA approval within ~1 year, demonstrating strong commercial and R&D execution.
Read all positive updates
Company Guidance
Syndax guided to continued top-line momentum and stable spending in 2026, citing key metrics: 2025 revenue was $172.4M (Revuforj $124.8M, partner‑reported Niktimvo $151.6M with $42.4M recorded by Syndax), Q4 Revuforj $44.2M (+38% QoQ) with prescriptions up ~35% and new patient starts up ~20% (≈1,050 patients treated since launch; ~50% penetration of KMT2A incident cases), Q4 Niktimvo $56M (+22% QoQ; ~13,500 infusions to >1,400 patients), Revuforj average treatment duration 4–6 months in 2025 (expected to extend to 6–12 months in year two), KMT2A transplant rate ~1/3 with 40–45% restarting therapy post‑transplant, NPM1 now expands annual addressable population to ~6,500 and has 97% formulary coverage, Niktimvo persistency ~60–70% at month 10 and ~20% share of 3L+ cGVHD so far; financial guidance includes R&D+SG&A of ~ $400M in 2026 (excl. ~$50M non‑cash stock comp), inventory at 2–3 weeks, a near‑term Niktimvo collaboration margin of ~25–30% of net sales that should improve as sales scale, $394M cash at 12/31/25, and an expectation to reach profitability without raising additional capital.Syndax Pharmaceuticals Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
41
Neutral
Cash Flow
23
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 217.17M | 172.35M | 23.68M | 0.00 | 0.00 | 139.71M |
| Gross Profit | 212.73M | 165.38M | 22.85M | 0.00 | 0.00 | 139.71M |
| EBITDA | -162.55M | -251.63M | -313.82M | -209.14M | -146.17M | 26.87M |
| Net Income | -243.25M | -285.42M | -318.76M | -209.36M | -149.34M | 24.93M |
Balance Sheet | ||||||
| Total Assets | 472.67M | 529.71M | 724.82M | 612.88M | 497.24M | 449.66M |
| Cash, Cash Equivalents and Short-Term Investments | 352.06M | 394.07M | 582.91M | 577.58M | 484.40M | 446.83M |
| Total Debt | 345.36M | 346.48M | 345.74M | 1.64M | 1.16M | 20.97M |
| Total Liabilities | 431.05M | 465.08M | 436.69M | 58.68M | 29.79M | 41.29M |
| Stockholders Equity | 41.62M | 64.63M | 288.12M | 554.20M | 467.45M | 408.37M |
Cash Flow | ||||||
| Free Cash Flow | -278.35M | -323.17M | -274.90M | -160.60M | -133.90M | 29.00M |
| Operating Cash Flow | -278.16M | -322.98M | -274.90M | -160.60M | -133.68M | 29.13M |
| Investing Cash Flow | 234.28M | 290.04M | -219.78M | 117.61M | -186.19M | -40.87M |
| Financing Cash Flow | 20.66M | 13.68M | 353.37M | 264.13M | 172.25M | 118.46M |
Syndax Pharmaceuticals Technical Analysis
Positive
24.23
Price Trends
22.78
Positive
21.65
Positive
17.82
Positive
Market Momentum
0.37
Positive
53.72
Neutral
35.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNDX, the sentiment is Positive. The current price of 24.23 is above the 20-day moving average (MA) of 24.17, above the 50-day MA of 22.78, and above the 200-day MA of 17.82, indicating a bullish trend. The MACD of 0.37 indicates Positive momentum. The RSI at 53.72 is Neutral, neither overbought nor oversold. The STOCH value of 35.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SNDX.
Syndax Pharmaceuticals Risk Analysis
Syndax Pharmaceuticals disclosed 55 risk factors in its most recent earnings report. Syndax Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Syndax Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $1.96B | 4.53 | 1813.84% | ― | 157.01% | 94.31% | |
54 Neutral | $1.01B | -68.46 | -34.23% | ― | 138.82% | 52.84% | |
54 Neutral | $1.37B | -36.71 | -444.41% | ― | ― | -13.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.76B | 69.02 | -44.10% | ― | 1205.52% | 81.79% | |
49 Neutral | $1.83B | -11.85 | -206.62% | ― | 397.28% | 27.68% | |
48 Neutral | $1.41B | -4.79 | -145.81% | ― | -10.44% | 19.99% |
* Healthcare Sector Average
SNDX
Syndax Pharmaceuticals
20.65
10.66
106.71%
GERN
Geron
1.58
0.27
20.61%
QURE
uniQure
22.82
12.76
126.84%
KALV
KalVista Pharmaceuticals
26.72
14.47
118.12%
ANAB
AnaptysBio
67.36
54.24
413.49%
NUVB
Nuvation Bio
5.04
3.00
147.06%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.